Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP - 1 Oct 2008

Farooqi Javed Iqbal, Farooqi Rukhsana Javed

Abstract excerpt

OBJECTIVE: To determine the efficacy of 12 weeks therapy with conventional interferon and ribavirin in chronic hepatitis C genotype 2 and 3 naive patients. STUDY DESIGN: A randomized clinical trial. PLACE AND DURATION OF STUDY: Postgraduate Medical Institute, Lady Reading Hospital, Peshawar, from January 2005 to October 2006. METHODOLOGY: Two hundred and twenty seven patients with chronic hepatitis C genotype 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Ribavirin

Share to Viral Load

Source

Identifiers

PMID: 18940119
DOI: 10.2008/JCPSP.620624

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.PMID 18940119Read ↗

Response to combination therapy in hepatitis virus C genotype 2 and 3.Semantic proximity Read ↗

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.Semantic proximity Read ↗

Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients.Semantic proximity Read ↗

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.Semantic proximity Read ↗

Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.Semantic proximity Read ↗

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.